

Amendments to the Claims

1. (Original) An agent for promoting HGF production comprising, as an effective ingredient, a disaccharide comprised of an uronic acid residue (wherein an uronic acid means an iduronic acid or a glucuronic acid, and has the same meaning hereinafter) and a glucosamine residue that are connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, or tri- to hexadeca-saccharides having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein at least one hydroxy group of the uronic acid residue(s) and/or the glucosamine residue(s) may be sulfated, alkylated, acylated or aminated, and/or amino group at position 2 of at least one of the glucosamine residue(s) may be sulfated, alkylated or acylated, or a salt thereof.

2. (Original) The agent for promoting HGF production according to claim 1, wherein the hydroxy group at position 2 of at least one of the uronic acid residue(s) and/or the hydroxy group at positions 3 and/or 6 of at least one of the glucosamine residue(s) may be sulfated.

3. (Currently amended) The agent for promoting HGF production according to claim 1 ~~or 2~~, wherein the hydroxy group at position 6 and/or the amino group at position 2 of at least one of the glucosamine residue(s) is sulfated.


4. (Currently amended) The agent for promoting HGF production according to ~~any one of claims 1 to 3~~ claim 1, wherein the oligosaccharide is di- to deca-saccharide.

5. (Currently amended) The agent for promoting HGF production according to ~~any one of claims 1 to 4~~ claim 1, wherein the oligosaccharide is a degradation product prepared from high-molecular-weight heparin or high-molecular-weight heparan sulfate by digestion with heparinase or heparitinase.

6. (Currently amended) The agent for promoting HGF production according to ~~any one of claims 1 to 4~~ claim 1, wherein the oligosaccharide is a degradation product prepared from high-molecular-weight heparin or high-molecular-weight heparan sulfate by digestion by any one of nitrous acid degradation, hydrogen peroxide degradation or β -elimination.


7. (Original) The agent for promoting HGF production according to claim 1, wherein the oligosaccharide is any one of compounds represented by the following (a) to (h);

(a) formula (I):




wherein R^1 represents hydrogen, sulfate group, alkyl, acyl, or optionally substituted amino group, R^2 represents hydrogen, sulfate group, alkyl or acyl group, R^3 and R^4 are different from each other and represent hydrogen or optionally substituted carboxyl group, and n represents 0 to 7,

(b) formula (II):




wherein all the symbols are respectively the same as defined above,

(c) formula (III):




wherein all the symbols are respectively the same as defined above,

(d) formula (IV):




wherein all the symbols are respectively the same as defined above,

(e) formula (V):




wherein m represents 0 to 6, and R¹, R², R³ and R⁴ are respectively the same as defined above,

(f) formula (VI):




wherein m represents 0 to 6, and R¹, R², R³ and R⁴ are respectively the same as defined above,

(g) formula (VII)



wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above, and

(h) formula (VIII)



wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above.

8. (Original) An agent for promoting HGF production comprising, as an effective ingredient, a sugar chain compound having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein the hydroxy group at position 6 of at least one of the glucosamine residue(s) is sulfated, or a salt thereof.

9. (Original) An agent for promoting HGF production comprising, as an effective ingredient, a sugar chain compound having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein the amino group at position 2 of at least one of the glucosamine residue(s) is sulfated, or a salt thereof.

10. (Original) An agent for promoting HGF production comprising, as an effective ingredient, a disaccharide compound comprised of an uronic acid residue and a glucosamine residue wherein the hydroxy group at position 6 of the glucosamine residue

and/or the amino group at position 2 of the glucosamine residue are/is sulfated are connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, or a salt thereof.

11. (Currently amended) The agent for promoting HGF production according to ~~any one of claims 1 to 10~~ claim 1, wherein the sugar chain compound or a salt thereof has no or reduced anti-blood coagulation activity and/or lipoprotein lipase releasing activity.

12. (Original) A method of promoting HGF production characterized by administering to a mammal an effective amount of a disaccharide composed of an uronic acid residue (wherein an uronic acid means an iduronic acid or a glucuronic acid, and has the same meaning hereinafter) and a glucosamine residue that are connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, or tri- to hexadeca-saccharides having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein at least one hydroxy group of the uronic acid residue(s) and/or the glucosamine residue(s) may be sulfated, alkylated, acylated or aminated, and/or the amino group at position 2 of at least one of the glucosamine residue(s) may be sulfated, alkylated or acylated, or a salt.

13. (Original) The method of promoting HGF production according to claim 12, wherein the hydroxy group at position 2 of at least one of the uronic acid residue(s) and/or the hydroxy group at positions 3 and/or 6 of at least one of the glucosamine residue(s) may be sulfated.

14. (Original) The method of promoting HGF production according to claim 12, wherein the hydroxy group at position 6 and/or the amino group at position 2 of at least one of the glucosamine residue(s) is sulfated.


15. (Original) The method of promoting HGF production according to claim 12, wherein the oligosaccharide is di- to deca-saccharide.

16. (Original) The method of promoting HGF production according to claim 12, wherein the oligosaccharide is a degradation product prepared from high-molecular-weight heparin or high-molecular-weight heparan sulfate by digestion with heparinase or heparitinase.

17. (Original) The method of promoting HGF production according to claim 12, wherein the oligosaccharide is a degradation product prepared from high-molecular-weight heparin or high-molecular-weight heparan sulfate by any one of nitrous acid degradation, hydrogen peroxide degradation or β -elimination.


18. (Original) The method of promoting HGF production according to claim 12, wherein the oligosaccharide is any one of compounds represented by the following (a) to (h);

(a) formula (I):




wherein R^1 represents hydrogen, sulfate group, alkyl, acyl, or optionally substituted amino group, R^2 represents hydrogen, sulfate group, alkyl or acyl group, R^3 and R^4 are different from each other and represent hydrogen or optionally substituted carboxyl group, and n represents 0 to 7,

(b) formula (II):




wherein all the symbols are respectively the same as defined above,

(c) formula (III):




wherein all the symbols are respectively the same as defined above,

(d) formula (IV):




wherein all the symbols are respectively the same as defined above,

(e) formula (V):




wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above,

(f) formula (VI):




wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above,

(g) formula (VII)



wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above, and

(h) formula (VIII)



wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above.

19. (Original) A method of promoting HGF production characterized by administering to a mammal an effective amount of a sugar chain compound having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein the hydroxy group at position 6 of at least one of the glucosamine residue(s) is sulfated, or a salt thereof.

20. (Original) A method of promoting HGF production characterized by administering to a mammal an effective amount of a sugar chain compound having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein the amino group at position 2 of at least one of the glucosamine residue(s) is sulfated, or a salt thereof.

21. (Original) A method of promoting HGF production characterized by administering to a mammal an effective amount of a disaccharide compound comprised of an uronic acid

residue and a glucosamine residue in which the hydroxy group at position 6 and/or the amino group at position 2 of the glucosamine residue are/is sulfated are connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, or a salt thereof.

22. (Currently amended) The method of promoting HGF production according to ~~any one of claims 12 to 21~~ claim 12, wherein the sugar chain compound or a salt thereof has no or reduced anti-blood coagulation activity and/or lipoprotein lipase releasing activity.

23. (Currently amended) A method for production of a medicament for promoting HGF production, which comprises mixing ~~Use of a~~ disaccharide composed of an uronic acid residue (wherein an uronic acid means an iduronic acid or a glucuronic acid, and has the same meaning hereinafter) and a glucosamine residue that are connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, or tri- to hexadeca-saccharides having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein at least one hydroxy group of the uronic acid residue(s) and/or the glucosamine residue(s) may be sulfated, alkylated, acylated or aminated, and/or the amino group at position 2 of at least one of the glucosamine residue(s) may be sulfated, alkylated or acylated, or a salt thereof, together with a carrier. ~~for the production of a medicament for promoting HGF production.~~

24. (Currently amended) ~~The use~~ method according to claim 23, wherein the hydroxy group at position 2 of at least one of the uronic acid residue(s) and/or the hydroxy group at positions 3 and/or 6 of at least one of the glucosamine residue(s) may be sulfated.

25. (Currently amended) ~~The use~~ method according to claim 23, wherein the hydroxy group at position 6 and/or the amino group at position 2 of at least one of the glucosamine residue(s) is sulfated.


26. (Currently amended) The ~~use~~ method according to claim 23, wherein the oligosaccharide is di- to deca-saccharide.

27. (Currently amended) The ~~use~~ method according to claim 23, wherein the oligosaccharide is a degradation product prepared from high-molecular-weight heparin or high-molecular-weight heparan sulfate by digestion with heparinase or heparitinase.

28. (Currently amended) The ~~use~~ method according to claim 23, wherein the oligosaccharide is a degradation product prepared from high-molecular-weight heparin or high-molecular-weight heparan sulfate by any one of nitrous acid degradation, hydrogen peroxide degradation or β -elimination.


29. (Currently amended) The ~~use~~ method according to claim 23 wherein the oligosaccharide is any one of compounds represented by the following (a) to (h);

(a) formula (I):




wherein R^1 represents hydrogen, sulfate group, alkyl, acyl, or optionally substituted amino group, R^2 represents hydrogen, sulfate group, alkyl or acyl group, R^3 and R^4 are different from each other and represent hydrogen or optionally substituted carboxyl group, and n represents 0 to 7,

(b) formula (II):




wherein all the symbols are respectively the same as defined above,

(c) formula (III):




wherein all the symbols are respectively the same as defined above,

(d) formula (IV):




wherein all the symbols are respectively the same as defined above,

(e) formula (V):




wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above,

(f) formula (VI):




wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above,

(g) formula (VII)



wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above, and

(h) formula (VIII)



wherein m represents 0 to 6, and R^1 , R^2 , R^3 and R^4 are respectively the same as defined above.

30. (Currently amended) A method for production of a medicament for promoting HGF production, which comprises mixing ~~Use of a sugar chain compound having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein the hydroxy group at position 6 of at least one of the glucosamine residue(s) is sulfated, or a salt thereof, together with a carrier. for the production of a medicament for promoting HGF production.~~

31. (Currently amended) A method for production of a medicament for promoting HGF production, which comprises mixing ~~Use of a sugar chain compound having a structure in which uronic acid residue(s) and glucosamine residue(s) are alternately and repeatedly connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, wherein at least one amino group at position 2 of the glucosamine residue(s) is sulfated, or a salt thereof, together with a carrier. for the production of a medicament for promoting HGF production.~~

32. (Currently amended) A method for production of a medicament for promoting HGF production, which comprises mixing ~~Use of~~ a disaccharide compound comprised of an uronic acid residue and a glucosamine residue wherein the hydroxy group at position 6 and/or the amino group at position 2 of the glucosamine residue are/is sulfated are connected by α 1,4-glycosidic linkage or β 1,4-glycosidic linkage, or a salt thereof, together with a carrier. ~~for the production of a medicament for promoting HGF production.~~

33. (Currently amended) The use method according to ~~any one of claims 23 to 32~~ claim 23, wherein the sugar chain compound or a salt thereof has no or reduced anti-blood coagulation activity and/or lipoprotein lipase releasing activity.